|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 9. Unadjusted and Adjusted Association Between PPI Adherence and Gastric Cancer in Unweighted Cohort (cDDD ≥180-days) a** | | | | | | | | |
| MPR c | No. of subjects | Person-years | No. of events | Incidence rate/1000 person-years (95% CI) | Crude hazard ratio (95% CI) | *P* | Adjusted hazard ratio (95% CI) b | *P* |
| > 80% | 9506 | 71793 | 176 | 2.45 (2.11, 2.84) | 1.17 (0.99, 1.39) | 0.060 | 1.01 (0.85, 1.22) | 0.878 |
| 50–80% | 5087 | 31631 | 84 | 2.66 (2.14, 3.29) | 1.25 (0.99, 1.57) | 0.056 | 1.00 (0.79, 1.27) | 0.993 |
| 20–50% | 15300 | 77652 | 212 | 2.73 (2.39, 3.12) | 1.26 (1.08, 1.47) | 0.004 | 1.02 (0.86, 1.19) | 0.862 |
| 0–20% | 36904 | 100927 | 270 | 2.68 (2.37, 3.01) | 1.15 (0.99, 1.33) | 0.065 | 0.91 (0.78, 1.07) | 0.244 |
| H2RA | 55321 | 288213 | 618 | 2.14 (1.98, 2.32) | Ref |  | Ref |  |
| PPI, proton pump inhibitor; H2RA, histamine-2 receptor antagonist; MPR, medication possession ratio; CI, confidence interval  a PPI long-term use was defined as only PPI use, PPI ≥ 180 cDDD-days, and combined use, PPI ≥ 180 cDDD-days and H2RA < 180 cDDD-days or PPI ≥ 180 cDDD-days and H2RA ≥ 180 cDDD-days. H2RA long-term use was defined as only H2RA use, H2RA ≥ 180 cDDD-days, and combined use of H2RA ≥ 180 cDDD-days and PPI < 180 cDDD-days. The medication possession ratio (MPR) of PPI long-term users was calculated as days of drug supply/days between first and last refills + days of supply from last refill. We categorized PPI long-term users according to their MPR degree.  b Adjusted for age, sex, calendar period of prescription, socioeconomic characteristics (income, smoking, and alcohol use), indication for drug use (GERD or peptic ulcer), Charlson Comorbidity Index, *H. pylori* eradication, and the use of other medications (aspirin, metformin, and statin).  c Unadjusted and adjusted subdistribution hazards ratios were obtained from the Fine and Gray model between PPI long-term users and H2RA long-term users from the unweighted study cohort, which accounted for competing risks. | | | | | | | | |